| Joseph Curtis Adams, MD | |
|
499 Gloster Creek Village, A-2, Tupelo, MS 38801 | |
| (662) 620-6800 | |
| (662) 620-6950 |
| Full Name | Joseph Curtis Adams |
|---|---|
| Gender | Male |
| Speciality | Interventional Cardiology |
| Experience | 28 Years |
| Location | 499 Gloster Creek Village, Tupelo, Mississippi |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1912003005 | NPI | - | NPPES |
| 05075871 | Medicaid | MS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 15456 (Mississippi) | Primary |
| 207RI0011X | Internal Medicine - Interventional Cardiology | 15456 (Mississippi) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| North Mississippi Medical Center | Tupelo, MS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| North Mississippi Clinics Llc | 3870773914 | 21 |
| North Mississippi Medical Center Services Llc | 6608048590 | 18 |
News Archive
Data from the 48-week ART trial, presented today at the Digestive Disease Week meeting, showed that remission and response rates were 37.2% and 53.2% respectively at week 12, in patients with moderate-to-severe, steroid-dependent active ulcerative colitis (UC) with insufficient response or intolerance to immunosuppressants and / or biologics when treated with between five and eight sessions with Adacolumn.
The Florida House of Representatives passed its own limited health care bill that relies on state money to expand coverage to the state's neediest residents. Also in the news, reports from Ohio, Montana, Texas, Nebraska and Arizona on the status of state decision-making regarding the expansion.
Researchers from the Stowers Institute for Medical Research have uncovered new details about several proteins implicated in tumor growth and metastasis, opening a potential avenue for the development of treatments for diseases such as breast cancer.
RegeneRx Biopharmaceuticals, Inc. ("the Company" or "RegeneRx") today announced that it met with the FDA in September and as a result of the meeting may begin Phase 3 to evaluate RGN-259 preservative-free eye drops for the treatment of patients with neurotrophic keratopathy (NK), an orphan disease of the cornea.
› Verified 2 days ago
| Entity Name | Cardiology Associates Of North Ms Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902971492 PECOS PAC ID: 4688648595 Enrollment ID: O20040825000433 |
News Archive
Data from the 48-week ART trial, presented today at the Digestive Disease Week meeting, showed that remission and response rates were 37.2% and 53.2% respectively at week 12, in patients with moderate-to-severe, steroid-dependent active ulcerative colitis (UC) with insufficient response or intolerance to immunosuppressants and / or biologics when treated with between five and eight sessions with Adacolumn.
The Florida House of Representatives passed its own limited health care bill that relies on state money to expand coverage to the state's neediest residents. Also in the news, reports from Ohio, Montana, Texas, Nebraska and Arizona on the status of state decision-making regarding the expansion.
Researchers from the Stowers Institute for Medical Research have uncovered new details about several proteins implicated in tumor growth and metastasis, opening a potential avenue for the development of treatments for diseases such as breast cancer.
RegeneRx Biopharmaceuticals, Inc. ("the Company" or "RegeneRx") today announced that it met with the FDA in September and as a result of the meeting may begin Phase 3 to evaluate RGN-259 preservative-free eye drops for the treatment of patients with neurotrophic keratopathy (NK), an orphan disease of the cornea.
› Verified 2 days ago
| Entity Name | North Mississippi Clinics Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326749540 PECOS PAC ID: 3870773914 Enrollment ID: O20110208000115 |
News Archive
Data from the 48-week ART trial, presented today at the Digestive Disease Week meeting, showed that remission and response rates were 37.2% and 53.2% respectively at week 12, in patients with moderate-to-severe, steroid-dependent active ulcerative colitis (UC) with insufficient response or intolerance to immunosuppressants and / or biologics when treated with between five and eight sessions with Adacolumn.
The Florida House of Representatives passed its own limited health care bill that relies on state money to expand coverage to the state's neediest residents. Also in the news, reports from Ohio, Montana, Texas, Nebraska and Arizona on the status of state decision-making regarding the expansion.
Researchers from the Stowers Institute for Medical Research have uncovered new details about several proteins implicated in tumor growth and metastasis, opening a potential avenue for the development of treatments for diseases such as breast cancer.
RegeneRx Biopharmaceuticals, Inc. ("the Company" or "RegeneRx") today announced that it met with the FDA in September and as a result of the meeting may begin Phase 3 to evaluate RGN-259 preservative-free eye drops for the treatment of patients with neurotrophic keratopathy (NK), an orphan disease of the cornea.
› Verified 2 days ago
| Entity Name | North Mississippi Medical Center Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013202886 PECOS PAC ID: 6608048590 Enrollment ID: O20111019000518 |
News Archive
Data from the 48-week ART trial, presented today at the Digestive Disease Week meeting, showed that remission and response rates were 37.2% and 53.2% respectively at week 12, in patients with moderate-to-severe, steroid-dependent active ulcerative colitis (UC) with insufficient response or intolerance to immunosuppressants and / or biologics when treated with between five and eight sessions with Adacolumn.
The Florida House of Representatives passed its own limited health care bill that relies on state money to expand coverage to the state's neediest residents. Also in the news, reports from Ohio, Montana, Texas, Nebraska and Arizona on the status of state decision-making regarding the expansion.
Researchers from the Stowers Institute for Medical Research have uncovered new details about several proteins implicated in tumor growth and metastasis, opening a potential avenue for the development of treatments for diseases such as breast cancer.
RegeneRx Biopharmaceuticals, Inc. ("the Company" or "RegeneRx") today announced that it met with the FDA in September and as a result of the meeting may begin Phase 3 to evaluate RGN-259 preservative-free eye drops for the treatment of patients with neurotrophic keratopathy (NK), an orphan disease of the cornea.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Joseph Curtis Adams, MD 499 Gloster Creek Vlg Ste A2, Cardiology Associates Of North Ms Pa, Tupelo, MS 38801-4749 Ph: (662) 620-6800 | Joseph Curtis Adams, MD 499 Gloster Creek Village, A-2, Tupelo, MS 38801 Ph: (662) 620-6800 |
News Archive
Data from the 48-week ART trial, presented today at the Digestive Disease Week meeting, showed that remission and response rates were 37.2% and 53.2% respectively at week 12, in patients with moderate-to-severe, steroid-dependent active ulcerative colitis (UC) with insufficient response or intolerance to immunosuppressants and / or biologics when treated with between five and eight sessions with Adacolumn.
The Florida House of Representatives passed its own limited health care bill that relies on state money to expand coverage to the state's neediest residents. Also in the news, reports from Ohio, Montana, Texas, Nebraska and Arizona on the status of state decision-making regarding the expansion.
Researchers from the Stowers Institute for Medical Research have uncovered new details about several proteins implicated in tumor growth and metastasis, opening a potential avenue for the development of treatments for diseases such as breast cancer.
RegeneRx Biopharmaceuticals, Inc. ("the Company" or "RegeneRx") today announced that it met with the FDA in September and as a result of the meeting may begin Phase 3 to evaluate RGN-259 preservative-free eye drops for the treatment of patients with neurotrophic keratopathy (NK), an orphan disease of the cornea.
› Verified 2 days ago
Dr. Marcus Louis Britton, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1542 Medical Park Cir, Tupelo, MS 38801 Phone: 662-844-4711 | |
John O Phillips, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 589 Garfield St, Suite 201, Tupelo, MS 38801 Phone: 662-680-5565 Fax: 662-680-5654 | |
Dr. Michael Ted Boler Jr., D.O. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 499 Gloster Creek Vlg Ste A2, Tupelo, MS 38801 Phone: 662-620-6800 Fax: 662-620-6950 | |
Christy Tucker Oswalt, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 65 S Thomas St, Tupelo, MS 38801 Phone: 662-842-7870 Fax: 662-842-7873 | |
Vernon A Rayford, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 845 S Madison St, Tupelo, MS 38801 Phone: 662-377-5930 | |
Stephen T Amann, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 589 Garfield St, Tupelo, MS 38801 Phone: 662-680-5565 Fax: 662-680-5654 | |
Douglas L Hill, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 499 Gloster Creek Vlg Ste A2, Cardiology Associates Of North Ms, Tupelo, MS 38801 Phone: 662-620-6800 Fax: 662-620-6920 |